We will pop a $2.00 bear minimum. It will then test the $6.00 range. Remember we almost were approved for the cancer drug . The fda just wants us to confirm no safety issue. Heck the phase 2 study saved lives and patients are doing far better. Drastically shrinks tumor growth. 100% increase in quarter revenues and growing. Analyst ratings were estimated at the levels we are now $16.00 very realistic. Short term $2.00 ..Either way very nice investment. Pennies won't be long here. In 6 weeks we will be well over a dollar no doubt
News 
Market Data 
Discover 
